268 related articles for article (PubMed ID: 26062396)
1. Rational drug design, synthesis and biological evaluation of dihydrofolate reductase inhibitors as antituberculosis agents.
Tawari NR; Bag S; Raju A; Lele AC; Bairwa R; Ray MK; Rajan MG; Nawale LU; Sarkar D; Degani MS
Future Med Chem; 2015; 7(8):979-88. PubMed ID: 26062396
[TBL] [Abstract][Full Text] [Related]
2. Fragment Discovery for the Design of Nitrogen Heterocycles as Mycobacterium tuberculosis Dihydrofolate Reductase Inhibitors.
Shelke RU; Degani MS; Raju A; Ray MK; Rajan MG
Arch Pharm (Weinheim); 2016 Aug; 349(8):602-13. PubMed ID: 27320965
[TBL] [Abstract][Full Text] [Related]
3. Preparation, biological evaluation and molecular docking study of imidazolyl dihydropyrimidines as potential Mycobacterium tuberculosis dihydrofolate reductase inhibitors.
Desai NC; Trivedi AR; Khedkar VM
Bioorg Med Chem Lett; 2016 Aug; 26(16):4030-5. PubMed ID: 27397497
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel selective Mtb-DHFR inhibitors as antitubercular agents through structure-based computational techniques.
Sharma K; Neshat N; Sharma S; Giri N; Srivastava A; Almalki F; Saifullah K; Alam MM; Shaquiquzzaman M; Akhter M
Arch Pharm (Weinheim); 2020 Feb; 353(2):e1900287. PubMed ID: 31867798
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design, synthesis and preliminary evaluation of selective inhibitors of dihydrofolate reductase from Mycobacterium tuberculosis.
El-Hamamsy MH; Smith AW; Thompson AS; Threadgill MD
Bioorg Med Chem; 2007 Jul; 15(13):4552-76. PubMed ID: 17451962
[TBL] [Abstract][Full Text] [Related]
6. 1,3,5-triazaspiro[5.5]undeca-2,4-dienes as selective Mycobacterium tuberculosis dihydrofolate reductase inhibitors with potent whole cell activity.
Yang X; Wedajo W; Yamada Y; Dahlroth SL; Neo JJ; Dick T; Chui WK
Eur J Med Chem; 2018 Jan; 144():262-276. PubMed ID: 29274493
[TBL] [Abstract][Full Text] [Related]
7. Interactions of 5-deazapteridine derivatives with Mycobacterium tuberculosis and with human dihydrofolate reductases.
da Cunha EF; de Castro Ramalho T; Bicca de Alencastro R; Maia ER
J Biomol Struct Dyn; 2004 Oct; 22(2):119-30. PubMed ID: 15317473
[TBL] [Abstract][Full Text] [Related]
8. Rational drug design based synthesis of novel arylquinolines as anti-tuberculosis agents.
Jain PP; Degani MS; Raju A; Ray M; Rajan MG
Bioorg Med Chem Lett; 2013 Nov; 23(22):6097-105. PubMed ID: 24095091
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of 11α-substituted bile acid derivatives as potential anti-tuberculosis agents.
Pore VS; Divse JM; Charolkar CR; Nawale LU; Khedkar VM; Sarkar D
Bioorg Med Chem Lett; 2015 Oct; 25(19):4185-90. PubMed ID: 26299346
[TBL] [Abstract][Full Text] [Related]
10. Applying the designed multiple ligands approach to inhibit dihydrofolate reductase and thioredoxin reductase for anti-proliferative activity.
Ng HL; Chen S; Chew EH; Chui WK
Eur J Med Chem; 2016 Jun; 115():63-74. PubMed ID: 26994844
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and evaluation of diarylpiperazine derivatives as potent anti-tubercular agents.
Penta A; Franzblau S; Wan B; Murugesan S
Eur J Med Chem; 2015 Nov; 105():238-44. PubMed ID: 26498570
[TBL] [Abstract][Full Text] [Related]
12. Rational design of coumarin derivatives as antituberculosis agents.
Mali HM; Sabale SS; Degani MS; Borkute R; Choudhari AS; Sarkar D; Krishna VS; Sriram D
Future Med Chem; 2018 Oct; 10(20):2431-2444. PubMed ID: 30325198
[TBL] [Abstract][Full Text] [Related]
13. Design of new phenothiazine-thiadiazole hybrids via molecular hybridization approach for the development of potent antitubercular agents.
Ramprasad J; Nayak N; Dalimba U
Eur J Med Chem; 2015 Dec; 106():75-84. PubMed ID: 26520841
[TBL] [Abstract][Full Text] [Related]
14. Thiazole-aminopiperidine hybrid analogues: design and synthesis of novel Mycobacterium tuberculosis GyrB inhibitors.
Jeankumar VU; Renuka J; Santosh P; Soni V; Sridevi JP; Suryadevara P; Yogeeswari P; Sriram D
Eur J Med Chem; 2013; 70():143-53. PubMed ID: 24148991
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of novel isoniazid derivatives with potent antitubercular activity.
Martins F; Santos S; Ventura C; Elvas-Leitão R; Santos L; Vitorino S; Reis M; Miranda V; Correia HF; Aires-de-Sousa J; Kovalishyn V; Latino DA; Ramos J; Viveiros M
Eur J Med Chem; 2014 Jun; 81():119-38. PubMed ID: 24836065
[TBL] [Abstract][Full Text] [Related]
16. Susceptibilities of Mycobacterium tuberculosis and Mycobacterium avium complex to lipophilic deazapteridine derivatives, inhibitors of dihydrofolate reductase.
Suling WJ; Reynolds RC; Barrow EW; Wilson LN; Piper JR; Barrow WW
J Antimicrob Chemother; 1998 Dec; 42(6):811-5. PubMed ID: 10052907
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.
Pieroni M; Wan B; Cho S; Franzblau SG; Costantino G
Eur J Med Chem; 2014 Jan; 72():26-34. PubMed ID: 24333612
[TBL] [Abstract][Full Text] [Related]
18. Design, Synthesis, and Biological Evaluation of 1,4-dihydropyridine Derivatives as Potent Antitubercular Agents.
Desai NC; Trivedi AR; Somani HC; Bhatt KA
Chem Biol Drug Des; 2015 Sep; 86(3):370-7. PubMed ID: 25534154
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and antitubercular activity of 4-alkoxy-triazoloquinolones able to inhibit the M. tuberculosis DNA gyrase.
Carta A; Bua A; Corona P; Piras S; Briguglio I; Molicotti P; Zanetti S; Laurini E; Aulic S; Fermeglia M; Pricl S
Eur J Med Chem; 2019 Jan; 161():399-415. PubMed ID: 30384044
[TBL] [Abstract][Full Text] [Related]
20. Virtual screening against Mycobacterium tuberculosis dihydrofolate reductase: suggested workflow for compound prioritization using structure interaction fingerprints.
Kumar A; Siddiqi MI
J Mol Graph Model; 2008 Nov; 27(4):476-88. PubMed ID: 18829358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
